Cite
HARVARD Citation
Nozza, S. et al. (n.d.). Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. Clinical microbiology and infection. pp. 510.e1-510.e9. [Online].